Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Sonki who wrote (99)	3/25/1998 11:58:00 AM
From: Robert Voigt	Respond to of 642

I agree with the Long Term approach to this stock. It has been very disappointing recently, especially compared to some of the high flyers like Pfizer, but I think the long term outlook is good.

To: Sonki who wrote (99)	3/25/1998 6:31:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 642

Sonki and all, Though it is encouraging to see that LLY had not closed at its low today, I would not consider going long until after the dust settles. It is very likely that the stock would break below $59 1/2. As Peter had noted, Heuer mentioned the sparsity of new drugs until 2001 as one of the reasons for downgrading the stock. Unless LLY's existing drugs gain more market share, or unless Evista's scripts increase considerably, there is no reason for the market to reward LLY with a high valuation. I think both short term and medium term, PFE would offer better rewards; but even PFE is a bit frothy now. Generally speaking, I think all the pharmaceuticals are due for a correction. I hope LLY would get a rebound, in which case it would be a good idea to get out and wait for an excellent buying opportunity later on. Regards. Anthony

To: Sonki who wrote (99)	3/25/1998 10:11:00 PM
From: James Baker	Read Replies (3) \| Respond to of 642

My opinion is that when analysts downgrade a major drug company with good products and a future - it is surely the time to buy for the long term investor. Look at MKR - they all hated it at 80 last fall and are tripping all over themselves to recommend MRK at 120 in Feb! Jim